20mg Retatrutide Weight Loss Peptide Lyophilized Powder Reta Vials Injection 99% Retatrutide

Incazelo Yomkhiqizo
I-Retatrutide iyinoveli ye-agonist peptide emithathu eqondise ku-glucagon receptor (GCGR), i-insulinotropic polypeptide receptor (GIPR) encike kuglucose (GIPR), kanye ne-glucagon-like peptide-1 receptor (GLP-1R). I-Retatrutide yenza i-GCGR yomuntu, i-GIPR, ne-GLP-1R isebenze ngamavelu e-EC50 angu-5.79, 0.0643, kanye no-0.775 nM, ngokulandelana, kanye negundane i-GCGR, GIPR, ne-GLP-1R ngamavelu e-EC50 angu-2.32, 0.0.191, kanye ne-nM. Isebenza njengethuluzi lokucwaninga elibalulekile ocwaningweni lokukhuluphala kanye nokuphazamiseka kwe-metabolic.

I-Retatrutide ivula ngempumelelo indlela yokusayina ye-GLP-1R futhi ivuse ukukhiqizwa kwe-insulin encike ku-glucose ngokusebenza kukho kokubili i-GIP ne-GLP-1 receptors. Le peptide yokwenziwa ikhombisa izakhiwo ezinamandla ze-hypoglycemic futhi ithuthukiswe njengenhlanganisela elwa nesifo sikashukela sohlobo 2 lwesifo sikashukela (T2D). Ikhuthaza ukukhululwa kwe-insulin futhi icindezela ukukhiqizwa kwe-glucagon ngendlela encike ku-glucose.

Ukwengeza, i-Retatrutide iboniswe ukubambezela ukuphuma kwesisu, yehlise kokubili amazinga eglucose wokuzila ukudla kanye ne-postprandial, ukunciphisa ukudla, futhi yenze ukulahlekelwa kwesisindo somzimba okuphawulekayo kubantu abane-T2D.

Umsebenzi Webhayoloji
I-Retatrutide (LY3437943) iyi-peptide eyodwa ye-lipid-conjugated esebenza njenge-agonist enamandla ye-GCGR yomuntu, i-GIPR, ne-GLP-1R. Uma iqhathaniswa ne-glucagon yabantu bomdabu kanye ne-GLP-1, i-Retatrutide ikhombisa amandla aphansi ku-GCGR ne-GLP-1R (0.3× kanye no-0.4×, ngokulandelana) kodwa ibonisa amandla athuthuke ngokuphawulekayo (8.9×) ku-GIPR uma kuqhathaniswa ne-insulinotropic polypeptide (GIP) encike ku-glucose.

Indlela Yokwenza
Ocwaningweni olubandakanya amagundane anesifo sikashukela ane-nephropathy, ukuphathwa kwe-Retatrutide kwehlise kakhulu i-albuminuria kanye nezinga lokuhlunga le-glomerular elithuthukisiwe. Lo mphumela wokuvikela ubangelwa ukwenziwa kusebenze kwendlela yokusayina encike ku-GLP-1R/GR, elamula izenzo zokulwa nokuvuvukala kanye nezokulwa ne-apoptotic ezicutshini zezinso.

I-Retatrutide iphinde iguqule ngokuqondile ukuqina kwe-glomerular, ithuthukise ikhono lokugxilisa umchamo. Imiphumela yokuqala iphakamisa ukuthi, uma kuqhathaniswa nokwelashwa okujwayelekile kwezifo zezinso ezingamahlalakhona njengama-ACE inhibitors nama-ARB, i-Retatrutide ikhiqiza ukwehla okugqame kakhulu kwe-albuminuria ngemva kwamasonto amane kuphela okwelashwa. Ngaphezu kwalokho, ibonise ukusebenza ngempumelelo okukhulu ekwehliseni umfutho wegazi we-systolic kune-ACE inhibitors noma ama-ARB, ngaphandle kwemiphumela emibi ebonwayo.

Okuqhamuka uma udla imishanguzo
Imiphumela evame kakhulu ye-Retatrutide iwuhlelo lwamathumbu, okuhlanganisa isicanucanu, isifo sohudo, ukuhlanza, nokuqunjelwa. Lezi zimpawu ngokuvamile ziba mnene kuye komaphakathi futhi zivame ukuxazulula ngokunciphisa umthamo. Cishe u-7% wezifundo uphinde wabika ukuzwa kokuluma kwesikhumba. Ukwanda kwezinga lokushaya kwenhliziyo kwabonwa emavikini angu-24 kumaqembu e-dose ephakeme, kamuva abuyela emazingeni okuqala.